Protriptyline Noradrenaline

Reboxetine is the only selective and reasonably potent noradrenaline reuptake inhibitor available clinically at the present time. Reboxetine has a chemical structure not dissimilar from viloxazine, an antidepressant which was of only limited clinical interest in the 1970s because of its weak efficacy and unacceptable side effects (nausea, vomiting and occasionally seizures). Unlike the secondary amine TCA antidepressants, such as maprotiline, desipramine, nortriptyline and protriptyline, reboxetine does not affect any other transporter or receptor system and therefore is largely devoid of TCA and SSRI-like side effects. In clinical trials, reboxetine has been shown to be as effective as the SSRIs in the... 

Specific serotonin reuptake inhibitors, as the class name implies, act predominantly by preventing serotonin reuptake and have more limited effects on noradrenaline reuptake. Tricyclic antidepressants in general inhibit noradrenaline reuptake, but effects on serotonin reuptake vary widely desipra-mine and protriptyline have minimal potential for raising serotonin concentrations, whereas clomipramine possesses a greater propensity for blocking serotonin reuptake than for noradrenaline. The... 

The pressor effects of adrenaline (epinephrine) and noradrenaline (norepinephrine) are increased in the presence of bretylium. Amfetamine and protriptyline antagonise the blood pressure lowering effect of bretylium. 

The effects of intravenous infusions of noradrenaline (norepinephrine) were increased approximately ninefold, and of adrenaline (epinephrine) approximately threefold, in 6 healthy subjects who had been taking protriptyline 60 mg daily for 4 days. > ... 

---